Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Oral Doses of Alpha-0261 Tablets in Patients With Chronic Spontaneous Urticaria, and the Effect of Food in Healthy Participants.

NCT07684560 is registered in ClinicalTrials.gov with AlphaMol Science Ltd. (Shanghai) as lead sponsor.

NCT NCT07684560
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07684560 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Oral Doses of Alpha-0261 Tablets in Patients With Chronic Spontaneous Urticaria, and the Effect of Food in Healthy Participants.
Lead sponsor
AlphaMol Science Ltd. (Shanghai)
Phase
Phase 1
Overall status
Not yet recruiting
Start date
July 1, 2026
Completion date
June 30, 2027
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic spontaneous urticaria (csu), healthy volunteers